Key Points
-
Multiple studies have investigated associations of BPH and/or lower urinary tract symptoms (LUTS) with metabolic syndrome as a whole and its components, for example visceral obesity, glucose intolerance, dyslipidaemia and hypertension
-
Although evidence for associations is conflicting for some components, metabolic syndrome as a whole is an important determinant in both the development and the progression of BPH-related LUTS (BPH–LUTS)
-
Metabolic-syndrome-related pathological changes, such as sex steroid alterations and low-grade inflammation, have been related to BPH–LUTS development and progression
-
Elevated oestrogen and oxidized LDL cholesterol levels increase inflammatory signalling of prostatic cells, stimulating chronic inflammation and proliferation, which contribute to BPH–LUTS development; androgens blunt this effect
-
Several intervention studies have demonstrated that testosterone replacement therapy can improve LUTS, but a therapeutic role of statin use for already established LUTS is still under debate
-
Promoting a healthy lifestyle, even in the asymptomatic phase, could alter a man's propensity to develop BPH–LUTS
Abstract
Epidemiological studies have shown that age is the principal unmodifiable risk factor of lower urinary tract symptoms (LUTS). Until the past decade, the process of lower urinary tract ageing was, therefore, considered unmodifiable — as ageing per se. However, the traditional dogma that BPH-related LUTS (BPH–LUTS) is an immutable consequence of old age is no longer acceptable. Results from multiple preclinical and clinical studies indicate that several modifiable, age-related metabolic aberrations (metabolic syndrome, obesity, dyslipidaemia, diabetes) are important determinants in both the development and the progression of BPH–LUTS. Metabolic syndrome and its related comorbidities, such as sex steroid alterations and low-grade inflammation, have been related to BPH–LUTS development and progression. With the correct treatment and recommended lifestyle changes, many individuals with metabolic syndrome might be able to prevent or delay the onset of metabolic-syndrome-related complications; however, whether promoting healthier lifestyles can really alter a man's propensity to develop BPH–LUTS remains to be clarified.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Parsons, J. K., Bergstrom, J., Silberstein, J. & Barrett-Connor, E. Prevalence and characteristics of lower urinary tract symptoms in men aged ≥80 years. Urology 72, 318–320 (2008).
Taylor, B. C. et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: the MrOS study. Urology 68, 804–809 (2006).
Reeves, P. et al. The current and future burden and cost of overactive bladder in five European countries. Eur. Urol. 50, 1050–1057 (2006).
Peters, T. J. et al. The International Continence Society 'Benign Prostatic Hyperplasia' Study: the botherosomeness of urinary symptoms. J. Urol. 157, 885–889 (1997).
Kupelian, V. et al. Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey. Arch. Intern. Med. 166, 2381–2387 (2006).
Irwin, D. E. et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur. Urol. 50, 1306–1314 (2006).
Coyne, K. S. et al. The prevalence of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) by racial/ethnic group and age: results from OAB-POLL. Neurourol. Urodyn. 32, 230–237 (2013).
Abrams, P. et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol. Urodyn. 21, 167–178 (2002).
Chapple, C. R. & Roehrborn, C. G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur. Urol. 49, 651–658 (2006).
Boyle, P. et al. The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study. BJU Int. 92, 409–414 (2003).
Coyne, K. S. et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int. 104, 352–360 (2009).
Zumrutbas, A. E. et al. Prevalence of lower urinary tract symptoms, overactive bladder and urinary incontinence in western Turkey: results of a population-based survey. Int. J. Urol. 21, 1027–1033 (2014).
Wang, Y. et al. Prevalence, risk factors and the bother of lower urinary tract symptoms in China: a population-based survey. Int. Urogynecol. J. 26, 911–919 (2015).
Alberti, K. G. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120, 1640–1645 (2009).
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285, 2486–2497 (2001).
Alberti, K. G., Zimmet, P. & Shaw, J. Metabolic syndrome — a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 23, 469–480 (2006).
Grundy, S. M. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110, 227–239 (2004).
Grundy, S. M. et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735–2752 (2005).
Ford, E. S. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 28, 1769–1778 (2005).
Seijkens, T., Kusters, P., Chatzigeorgiou, A., Chavakis, T. & Lutgens, E. Immune cell crosstalk in obesity: a key role for costimulation? Diabetes 63, 3982–3991 (2014).
Dietrich, P. & Hellerbrand, C. Non-alcoholic fatty liver disease, obesity and the metabolic syndrome. Best Pract. Res. Clin. Gastroenterol. 28, 637–653 (2014).
Konrad, D. & Wueest, S. The gut–adipose–liver axis in the metabolic syndrome. Physiology (Bethesda) 29, 304–313 (2014).
McNelis, J. C. & Olefsky, J. M. Macrophages, immunity, and metabolic disease. Immunity 41, 36–48 (2014).
McGill, A. T. Causes of metabolic syndrome and obesity-related co-morbidities Part 1: a composite unifying theory review of human-specific co-adaptations to brain energy consumption. Arch. Publ. Health 72, 30–38 (2014).
Ford, E. S., Giles, W. H. & Dietz, W. H. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 287, 356–359 (2002).
Mozumdar, A. & Liguori, G. Persistent increase of prevalence of metabolic syndrome among U.S. adults: NHANES III to NHANES 1999–2006. Diabetes Care 34, 216–229 (2011).
Corona, G. et al. Testosterone and metabolic syndrome: a meta-analysis study. J. Sex. Med. 8, 272–283 (2011).
Corona, G. et al. Hypogonadism and metabolic syndrome. J. Endocrinol. Invest. 34, 557–567 (2011).
Corona, G., Vignozzi, L., Sforza, A., Mannucci, E. & Maggi, M. Obesity and late-onset hypogonadism. Mol. Cell. Endocrinol. 418, 120–133 (2015).
Rastrelli, G. et al. Development of and recovery from secondary hypogonadism in ageing men: prospective results from the EMAS. J. Clin. Endocrinol. Metab. 100, 3172–3182 (2015).
Kim, J. C. et al. Effects of obesity on lower urinary tract symptoms in Korean BPH patients. Asian J. Androl. 11, 663–668 (2009).
Parsons, J. K. Benign prostatic hyperplasia and male lower urinary tract symptoms: epidemiology and risk factors. Curr. Bladder Dysfunct. Rep. 5, 212–218 (2010).
Kim, J. M., Song, P. H., Kim, H. T. & Moon, K. H. Effect of obesity on prostate-specific antigen, prostate volume, and international prostate symptom score in patients with benign prostatic hyperplasia. Korean J. Urol. 52, 401–405 (2011).
Dahle, S. E. et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J. Urol. 168, 599–604 (2002).
Wang, S. et al. Body mass index and risk of BPH: a meta-analysis. Prostate Cancer Prostatic Dis. 15, 265–272 (2012).
Kristal, A. R. et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. J. Urol. 177, 1395–1400 (2007).
Parsons, J. K. et al. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: the Osteoporotic Fractures in Men study. Eur. Urol. 60, 1173–1180 (2011).
Penson, D. F. et al. Obesity, physical activity and lower urinary tract symptoms: results from the Southern Community Cohort Study. J. Urol. 186, 2316–2322 (2011).
Maserejian, N. N. et al. Treatment status and progression or regression of lower urinary tract symptoms in a general adult population sample. J. Urol. 191, 107–113 (2014).
Kok, E. T. et al. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study. J. Urol. 181, 710–716 (2009).
Wong, S. Y., Woo, J., Leung, J. C. & Leung, P. C. Depressive symptoms and lifestyle factors as risk factors of lower urinary tract symptoms in Southern Chinese men: a prospective study. Aging Male 13, 113–119 (2010).
Burke, J. P. et al. Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia. Am. J. Epidemiol. 164, 41–46 (2006).
Mondul, A. M., Giovannucci, E. & Platz, E. A. A prospective study of obesity, and the incidence and progression of lower urinary tract symptoms. J. Urol. 191, 715–721 (2014).
Lotti, F. et al. Elevated body mass index correlates with higher seminal plasma interleukin 8 levels and ultrasonographic abnormalities of the prostate in men attending an andrology clinic for infertility. J. Endocrinol. Invest. 34, 336–342 (2011).
Gacci, M. et al. Central obesity is predictive of persistent storage lower urinary tract symptoms (LUTS) after surgery for benign prostatic enlargement: results of a multicentre prospective study. BJU Int. 116, 271–277 (2015).
Hammarsten, J., Hogstedt, B., Holthuis, N. & Mellstrom, D. Components of the metabolic syndrome — risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1, 157–162 (1998).
Joseph, M. A. et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am. J. Epidemiol. 157, 906–914 (2003).
Seim, A., Hoyo, C., Ostbye, T. & Vatten, L. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int. 96, 88–92 (2005).
Kupelian, V., Araujo, A. B., Wittert, G. A. & McKinlay, J. B. Association of moderate to severe lower urinary tract symptoms with incident type 2 diabetes and heart disease. J. Urol. 193, 581–586 (2015).
Meigs, J. B., Mohr, B., Barry, M. J., Collins, M. M. & McKinlay, J. B. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J. Clin. Epidemiol. 54, 935–944 (2001).
Chiu, Y. L., Kao, S., Lin, H. C., Liu, S. P. & Huang, C. Y. Benign prostatic enlargement is not associated with diabetes: a population-based study. Andrology 3, 933–936 (2015).
Parsons, J. K. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J. Urol. 178, 395–401 (2007).
Nandeesha, H., Koner, B. C., Dorairajan, L. N. & Sen, S. K. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin. Chim. Acta 370, 89–93 (2006).
Lotti, F. Metabolic syndrome and prostate abnormalities in male subjects of infertile couples. Asian J. Androl. 16, 295–304 (2014).
Corona, G. et al. Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. Int. J. Endocrinol. 2014, 329456 (2014).
Parsons, J. K., Bergstrom, J. & Barrett-Connor, E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. Br. J. Urol. Int. 101, 313–318 (2008).
Martin, S., Lange, K., Haren, M.T., Taylor, A.W. & Wittert, G. Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men. J. Urol. 191, 130–137 (2014).
Gann, P. H. et al. A prospective study of plasma hormone levels, nonhormonal factors, and development of benign prostatic hyperplasia. Prostate 26, 40–49 (1995).
Rohrmann, S., Smit, E., Giovannucci, E. & Platz, E. A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int. J. Obes. (Lond.) 29, 310–316 (2005).
Kupelian, V. et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston Area Community Health Survey. J. Urol. 182, 616–625 (2009).
Temml, C. et al. Are lower urinary tract symptoms influenced by metabolic syndrome? Urology 73, 544–548 (2009).
Park, H. K. et al. Relationship between lower urinary tract symptoms and metabolic syndrome in a community-based elderly population. Urology 72, 556–560 (2008).
Eom, C. S. et al. Metabolic syndrome and accompanying hyperinsulinemia have favorable effects on lower urinary tract symptoms in a generally healthy screened population. J. Urol. 186, 175–179 (2011).
Ohgaki, K. et al. Association between metabolic syndrome and male lower urinary tract symptoms in Japanese subjects using three sets of criteria for metabolic syndrome and International Prostate Symptom Score. Urology 77, 1432–1438 (2011).
Yang, T. K. et al. Metabolic syndrome associated with reduced lower urinary tract symptoms in middle-aged men receiving health checkup. Urology 80, 1093–1097 (2012).
Gao, Y. et al. Are metabolic syndrome and its components associated with lower urinary tract symptoms? Results from a Chinese male population survey. Urology 79, 194–201 (2012).
Kim, J. H., Doo, S. W., Yun, J. H. & Yang, W. J. Lower likelihood of having moderate-to-severe lower urinary tract symptoms in middle-aged healthy Korean men with metabolic syndrome. Urology 84, 665–669 (2014).
Gacci, M. et al. Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 115, 24–31 (2015).
Russo, G. I. et al. Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components: a systematic review and meta-analysis. Aging Male 14, 1–10 (2015).
Pashootan, P., Ploussard, G., Cocaul, A., de Gouvello, A. & Desgrandchamps, F. Association between metabolic syndrome and severity of lower urinary tract symptoms (LUTS): an observational study in a 4666 European men cohort. BJU Int. 116, 124–130 (2015).
De Nunzio, C. et al. Metabolic syndrome and lower urinary tract symptoms in patients with benign prostatic enlargement: a possible link to storage symptoms. Urology 84, 1181–1187 (2014).
Lee, S. H. et al. Relationship between metabolic syndrome and lower urinary tract symptoms: Hallym Aging Study. Biomed. Res. Int. 2015, 130917 (2015).
Park, J. H. et al. Body mass index, waist-to-hip ratio, and metabolic syndrome as predictors of middle-aged men's health. Korean J. Urol. 56, 386–392 (2015).
Ozden, C. et al. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur. Urol. 51, 199–203 (2007).
Kanazawa, M. et al. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev. Nutr. Diet. 94, 1–12 (2005).
Anderson, E. A. et al. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J. Clin. Invest. 87, 2246–2252 (1991).
Vignozzi, L. et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 73, 789–800 (2013).
Nathan, D. M. Diabetes: advances in diagnosis and treatment. JAMA 314, 1052–1062 (2015).
Nørby, B., Nordling, J. & Mortensen, S. Lower urinary tract symptoms in the Danish population: a population-based study of symptom prevalence, health-care seeking behavior and prevalence of treatment in elderly males and females. Eur. Urol. 47, 817–823 (2005).
Fowke, J. H., Munro, H., Signorello, L. B., Blot, W. J. & Penson, D. F. Association between socioeconomic status (SES) and lower urinary tract symptom (LUTS) severity among black and white men. J. Gen. Intern. Med. 26, 1305–1310 (2011).
Welty, F. K., Alfaddagh, A. & Elajami, T. K. Targeting inflammation in metabolic syndrome. Transl. Res. 167, 257–280 (2016).
Fibbi, B., Penna, G., Morelli, A., Adorini, L. & Maggi, M. Chronic inflammation in the pathogenesis of benign prostatic hyperplasia. Int. J. Androl. 33, 475–488 (2010).
Vignozzi, L. et al. Benign prostatic hyperplasia: a new metabolic disease? J. Endocrinol. Invest. 37, 313–322 (2014).
Crawford, E. D. et al. Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J. Urol. 175, 1422–1426 (2006).
Nickel, J. C. et al. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur. Urol. 54, 1379–1384 (2008).
Schenk, J. M. et al. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. Am. J. Epidemiol. 171, 571–582 (2010).
Kupelian, V. et al. Association of urological symptoms and chronic illness in men and women: contributions of symptom severity and duration — results from the BACH Survey. J. Urol. 181, 694–700 (2009).
Liao, C. H., Chung, S. D. & Kuo, H. C. Serum C-reactive protein levels are associated with residual urgency symptoms in patients with benign prostatic hyperplasia after medical treatment. Urology 78, 1373–1378 (2011).
Hung, S. F., Chung, S. D. & Kuo, H. C. Increased serum C-reactive protein level is associated with increased storage lower urinary tract symptoms in men with benign prostatic hyperplasia. PLoS ONE 9, e85588 (2014).
Kim, J. H., Doo, S. W., Yang, W. J., Song, Y. S. & Kwon, S. S. Association between high-sensitivity C-reactive protein and lower urinary tract symptoms in healthy Korean populations. Urology 86, 139–144 (2015).
Vignozzi, L. et al. Antiinflammatory effect of androgen receptor activation in human benign prostatic hyperplasia cells. J. Endocrinol. 214, 31–43 (2012).
Comeglio, P. et al. Opposite effects of tamoxifen on metabolic syndrome induced bladder and prostate alterations: a role for GPR30/GPER? Prostate 74, 10–28 (2014).
Penna, G. et al. Human benign prostatic hyperplasia stromal cells as inducers and targets of chronic immuno-mediated inflammation. J. Immunol. 182, 4056–4064 (2009).
Vignozzi, L. et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit. J. Endocrinol. 212, 71–84 (2012).
Morelli, A. et al. Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome. J. Steroid Biochem. Mol. Biol. 132, 80–92 (2012).
Filippi, S. et al. Testosterone partially ameliorates metabolic profile and erectile responsiveness to PDE5 inhibitors in an animal model of male metabolic syndrome. J. Sex. Med. 6, 3274–3288 (2009).
Vignozzi, L. et al. Farnesoid X receptor activation improves erectile function in animal models of metabolic syndrome and diabetes. J. Sex. Med. 8, 57–77 (2011).
Gacci, M. et al. Metabolic syndrome and lower urinary tract symptoms: the role of inflammation. Prostate Cancer Prostatic Dis. 16, 101–106 (2013).
Ehren, I., Iversen, H., Jansson, O., Adolfsson, J. & Wiklund, N. P. Localization of nitric oxide synthase activity in the human lower urinary tract and its correlation with neuroeffector responses. Urology 44, 683–687 (1994).
Haghsheno, M.-A. et al. Lower urinary tract symptoms are associated with low levels of serum serotonin, high levels of adiponectin and fasting glucose, and benign prostatic enlargement. Scand. J. Urol. 49, 155–161 (2015).
Muldoon, M. F. et al. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J. Clin. Endocrinol. Metab. 91, 718–721 (2006).
Herrera, R., Hernandez-Rodrigues, J. & Medina-Serrano, J. Association of metabolic syndrome with reduced central serotonergic activity. Metab. Brain Dis. 26, 29–35 (2011).
Coto, E. et al. 5-hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin. Sci. (Lond.) 104, 241–245 (2003).
Yuan, X., Yamada, K., Ishiyama-Shigemoto, S., Koyama, W. & Nonaka, K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and type II diabetes. Diabetologia 43, 373–376 (2000).
Rosmond, R., Bouchard, C. & Björntorp, P. Increased abdominal obesity in subjects with a mutation in the 5-HT2A receptor gene promoter. Ann. N. Y. Acad. Sci. 967, 571–575 (2002).
Corona, G. et al. Low prolactin is associated with sexual dysfunction and psychological or metabolic disturbances in middle-aged and elderly men: the European Male Aging Study (EMAS). J. Sex. Med. 11, 240–253 (2014).
Yatham, L. N. & Steiner, M. Neuroendocrine probes of serotonergic function: a critical review. Life Sci. 53, 447–463 (1993).
Paul-Savoie, E. et al. A deficit in peripheral serotonin levels in major depressive disorder but not in chronic widespread pain. Clin. J. Pain 27, 529–534 (2011).
Wong, S. Y. et al. Lower urinary tract symptoms and depressive symptoms in elderly men. J. Affect. Disord. 96, 83–88 (2006).
Rom, M., Schatzl, G., Swietek, N., Rucklinger, E. & Kratzik, C. Lower urinary tract symptoms and depression. BJU Int. 110, E918–E921 (2012).
Zorn, B. H., Montgomery, H., Pieper, K., Gray, M. & Steers, W. D. Urinary incontinence and depression. J. Urol. 162, 82–84 (1999).
Hammarsten, J., Högstedt, B., Holthuis, N. & Mellström, D. Components of the metabolic syndrome—risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 1, 157–162 (1998).
McVary, K. T., Rademaker, A., Lloyd, G. L. & Gann, P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 174, 1327–1433 (2005).
Ullrich, P. M., Lutgendorf, S. K. & Kreder, K. J. Physiologic reactivity to a laboratory stress task among men with benign prostatic hyperplasia. Urology 70, 487–491 (2007).
Cellek, S. et al. Selective nitrergic neurodegeneration in diabetes mellitus — a nitric oxide-dependent phenomenon. Br. J. Pharmacol. 128, 1804–1812 (1999).
Moul, S. & McVary, K. T. Lower urinary tract symptoms, obesity and the metabolic syndrome. Curr. Opin. Urol. 20, 7–12 (2010).
Maserejian, N. N., Kupelian, V., Miyasato, G., McVary, K. T. & McKinlay, J. B. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J. Urol. 188, 490–495 (2012).
Smith, D. P. et al. Relationship between lifestyle and health factors and severe lower urinary tract symptoms (LUTS) in 106,435 middle-aged and older Australian men: population-based study. PLoS ONE 9, e109278 (2014).
Parsons, J. K. & Kashefi, C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur. Urol. 53, 1228–1235 (2008).
Platz, E. A. et al. Physical activity and benign prostatic hyperplasia. Arch. Intern. Med. 158, 2349–2356 (1998).
Khoo, J. et al. Comparing effects of low- and high-volume moderate-intensity exercise on sexual function and testosterone in obese men. J. Sex. Med. 10, 1823–1832 (2013).
Kristal, A. R. et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial. Am. J. Epidemiol. 167, 925–934 (2008).
Rohrmann, S., Giovannucci, E., Willett, W. C. & Platz, E. A. Fruit and vegetable consumption, intake of micronutrients, and benign prostatic hyperplasia in US men. Am. J. Clin. Nutr. 85, 523–529 (2007).
Suzuki, S., Platz, E. A., Kawachi, I., Willett, W. C. & Giovannucci, E. Intakes of energy and macronutrients and the risk of benign prostatic hyperplasia. Am. J. Clin. Nutr. 75, 689–697 (2002).
Maserejian, N. N., Giovannucci, E. L. & McKinlay, J. B. Dietary macronutrients, cholesterol, and sodium and lower urinary tract symptoms in men. Eur. Urol. 55, 1179–1189 (2009).
Bravi, F. et al. Food groups and risk of benign prostatic hyperplasia. Urology 67, 73–79 (2006).
Ambrosini, G. L., de Klerk, N. H., Mackerras, D., Leavy, J. & Fritschi, L. Dietary patterns and surgically treated benign prostatic hyperplasia: a case control study in Western Australia. BJU Int. 101, 853–860 (2008).
Shirazi, M., Ariafar, A., Zeyghami, S., Hosseini, M. M. & Khezri, A. A. Association of diet with prostate specific antigen and prostate volume. Nephrourol. Mon. 6, e19411 (2014).
Luke, S. et al. Effects of bariatric surgery on untreated lower urinary tract symptoms: a prospective multicentre cohort study. BJU Int. 115, 466–472 (2015).
St Sauver, J. L. et al. Statin use and decreased risk of benign prostatic enlargement and lower urinary tract symptoms. BJU Int. 107, 443–540 (2011).
Hall, S. A. et al. Are statin medications associated with lower urinary tract symptoms in men and women? Results from the Boston Area Community Health (BACH) Survey. Ann. Epidemiol. 21, 149–155 (2011).
Mondul, A. M., Giovannucci, E. & Platz, E. A. A prospective study of statin drug use and lower urinary tract symptoms in older men. Am. J. Epidemiol. 178, 797–803 (2013).
Mills, I. W., Crossland, A., Patel, A. & Ramonas, H. Atorvastatin treatment for men with lower urinary tract symptoms and benign prostatic enlargement. Eur. Urol. 52, 503–509 (2007).
Stamatiou, K. N., Zaglavira, P., Skolarikos, A. & Sofras, F. The effects of lovastatin on conventional medical treatment of lower urinary tract symptoms with finasteride. Int. Braz. J. Urol. 34, 555–561 (2008).
Pearl, J. A. et al. Testosterone supplementation does not worsen lower urinary tract symptoms. J. Urol. 190, 1828–1833 (2013).
Francomano, D., Ilacqua, A., Bruzziches, R., Lenzi, A. & Aversa, A. Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology 83, 167–173 (2014).
Ko, Y. H., Moon, D. G. & Moon, K. H. Testosterone replacement alone for testosterone deficiency syndrome improves moderate lower urinary tract symptoms: one year follow-up. World J. Mens Health 31, 47–52 (2013).
Shigehara, K. et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 14, 53–58 (2011).
Haider, A., Gooren, L. J., Padungtod, P. & Saad, F. Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalisation of plasma testosterone levels in hypogonadal elderly men. Andrologia 41, 7–13 (2009).
Kalinchenko, S., Vishnevskiy, E. L., Koval, A. N., Mskhalaya, G. J. & Saad, F. Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: a pilot study. Aging Male 11, 57–61 (2008).
Karazindiyanoglu, S. & Çayan, S. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism. Aging Male 11, 146–149 (2008).
Seftel, A. D., Kathrins, M. & Niederberger, C. Critical update of the 2010 Endocrine Society Clinical Practice Guidelines for Male Hypogonadism: a systematic analysis. Mayo Clin. Proc. 90, 1104–1115 (2015).
Dean, J. D. et al. The International Society for Sexual Medicine's process of care for the assessment and management of testosterone deficiency in adult men. J. Sex. Med. 12, 1660–1686 (2015).
Zhang, L. et al. Population-based survey of the prevalence, potential risk factors, and symptom-specific bother of lower urinary tract symptoms in adult Chinese women. Eur. Urol. 68, 97–112 (2015).
Milsom, I. et al. Global prevalence and economic burden of urgency urinary incontinence: a systematic review. Eur. Urol. 65, 79–95 (2014).
Danforth, K. N., Townsend, M. K., Curhan, G. C., Resnick, N.M. & Grodstein, F. Type 2 diabetes mellitus and risk of stress, urge and mixed urinary incontinence. J. Urol. 181, 193–197 (2009).
Brown, J. S. et al. Prevalence and risk factors for urinary incontinence in women with type 2 diabetes and impaired fasting glucose: findings from the National Health and Nutrition Examination Survey (NHANES) 2001–2002. Diabetes Care 29, 1307–1312 (2006).
James, R. & Hijaz, A. Lower urinary tract symptoms in women with diabetes mellitus: a current review. Curr. Urol. Rep. 15, 440 (2014).
Subak, L. L. et al. Weight loss to treat urinary incontinence in overweight and obese women. N. Engl. J. Med. 360, 481–490 (2009).
Subak, L. L. et al. Urinary incontinence before and after bariatric surgery. JAMA Intern. Med. 175, 1378–1387 (2015).
Phelan, S. et al. Weight loss prevents urinary incontinence in women with type 2 diabetes: results from the Look AHEAD trial. J. Urol. 187, 939–944 (2012).
Phelan, S. et al. Long-term prevalence and predictors of urinary incontinence among women in the Diabetes Prevention Program Outcomes Study. Int. J. Urol. 22, 206–212 (2015).
Tai, H. C. et al. Metabolic syndrome components worsen lower urinary tract symptoms in women with type 2 diabetes. J. Clin. Endocrinol. Metab. 95, 1143–1150 (2010).
Apostolidis, A. et al. Gender and age differences in the perception of bother and health care seeking for lower urinary tract symptoms: results from the hospitalised and outpatients' profile and expectations study. Eur. Urol. 56, 937–947 (2009).
Hong, G. S., Shim, B. S., Chung, W. S. & Yoon, H. Correlation between metabolic syndrome and lower urinary tract symptoms of males and females in the aspect of gender-specific medicine: a single institutional study. Korean J. Urol. 51, 631–635 (2010).
Kim, Y. H., Kim, J. J., Kim, S. M., Choi, Y. & Jeon, M. J. Association between metabolic syndrome and pelvic floor dysfunction in middle-aged to older Korean women. Am. J. Obstet. Gynecol. 205, 71.e1–71.e8 (2011).
Author information
Authors and Affiliations
Contributions
L.V. and M.G. researched data for the article. L.V. and M.M. provided a substantial contribution to discussion of the content, wrote the article and reviewed/edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Related links
Rights and permissions
About this article
Cite this article
Vignozzi, L., Gacci, M. & Maggi, M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13, 108–119 (2016). https://doi.org/10.1038/nrurol.2015.301
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2015.301
This article is cited by
-
Gut Microbiota Disorders in Obesity-Associated Benign Prostatic Hyperplasia in Rats
Biochemical Genetics (2024)
-
Features of patients referring to the outpatient office due to benign prostatic hyperplasia: analysis of a national prospective cohort of 5815 cases
Prostate Cancer and Prostatic Diseases (2023)
-
Genetically elevated bioavailable testosterone level was associated with the occurrence of benign prostatic hyperplasia
Journal of Endocrinological Investigation (2023)
-
Estrogen and G protein-coupled estrogen receptor accelerate the progression of benign prostatic hyperplasia by inducing prostatic fibrosis
Cell Death & Disease (2022)
-
Association between sleep status and lower urinary tract symptoms among men aged 40 or older in Zhengzhou
Sleep and Biological Rhythms (2022)